Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation (Q39438948)

12 September 2017

Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation (English)

1 reference

12 September 2017

0 references

0 references

Innes GD

1

1 reference

12 September 2017

Vertesi L

series ordinal

2

1 reference

12 September 2017

Dillon EC

series ordinal

3

1 reference

12 September 2017

Metcalfe C

series ordinal

4

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

Annals of Emergency Medicine

12 September 2017

1 reference

12 September 2017

29

1 reference

12 September 2017

1

1 reference

12 September 2017

126-134

1 reference

Acute complications associated with new-onset atrial fibrillation

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Management of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Redefining the role of digoxin in the treatment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Supraventricular tachyarrhythmias and rate-related hypotension: cardiovascular effects and efficacy of intravenous verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Verapamil in atrial fibrillation and atrial flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Double-blind crossover randomized trial of intravenously administered verapamil. Its use for atrial fibrillation and flutter following open heart surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Usefulness of propafenone for recurrent paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Efficacy of flecainide for the reversion of acute onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Comparison of flecainide and procainamide in cardioversion of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Clonidine for patients with rapid atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Atrial fibrillation: new management strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Clinical safety profile of sotalol in the treatment of arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Clinical safety profile of sotalol in patients with arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Propafenone-Induced Torsade de Pointes: Cross-Reactivity with Quinidine

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2897%2970318-4

7 January 2021

10.1016/S0196-0644(97)70318-4

Identifiers

DOI

1 reference

12 September 2017

1 reference